Humacyte, Inc. (HUMA)
Total Valuation
Humacyte has a market cap or net worth of $485.15 million. The enterprise value is $330.01 million.
Market Cap | 485.15M |
Enterprise Value | 330.01M |
Important Dates
The latest earnings date was Friday, May 13, 2022, before market open.
Last Earnings Date | May 13, 2022 |
Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 103.01 million shares outstanding. The number of shares has increased by 1,653.35% in one year.
Shares Outstanding | 103.01M |
Shares Change (YoY) | +1,653.35% |
Shares Change (QoQ) | +157.70% |
Owned by Insiders (%) | 49.75% |
Owned by Institutions (%) | 11.61% |
Float | 50.95M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 361.78 |
PB Ratio | 4.67 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 246.10 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.45, with a Debt / Equity ratio of 0.49.
Current Ratio | 19.45 |
Quick Ratio | 19.18 |
Debt / Equity | 0.49 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -11.00% |
Return on Capital (ROIC) | -21.20% |
Revenue Per Employee | $9,248 |
Profits Per Employee | -$179,366 |
Employee Count | 145 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.90% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | -50.90% |
50-Day Moving Average | 6.48 |
200-Day Moving Average | 7.18 |
Average Volume (30 Days) | 376,865 |
Short Selling Information
The latest short interest is 5.89 million, so 5.71% of the outstanding shares have been sold short.
Short Interest | 5.89M |
Short % of Shares Out | 5.71% |
Short % of Float | 11.55% |
Short Ratio (days to cover) | 18.25 |
Income Statement
In the last 12 months, Humacyte had revenue of $1.34 million and -26.01 million in losses. Earnings per share was -$0.41.
Revenue | 1.34M |
Gross Profit | 1.34M |
Operating Income | -83.20M |
Net Income | -26.01M |
EBITDA | -12.51M |
EBIT | -20.76M |
Earnings Per Share (EPS) | -$0.41 |
Balance Sheet
The company has $206.22 million in cash and $51.08 million in debt, giving a net cash position of $155.14 million or $1.51 per share.
Cash & Cash Equivalents | 206.22M |
Total Debt | 51.08M |
Net Cash | 155.14M |
Net Cash Per Share | $1.51 |
Book Value | 103.89M |
Book Value Per Share | 1.01 |
Working Capital | 198.53M |
Cash Flow
In the last 12 months, operating cash flow was -$85.44 million and capital expenditures -$213,000, giving a free cash flow of -$85.66 million.
Operating Cash Flow | -85.44M |
Capital Expenditures | -213,000 |
Free Cash Flow | -85.66M |
FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -6,204.47% and -1,939.45%.
Gross Margin | 100.00% |
Operating Margin | -6,204.47% |
Pretax Margin | n/a |
Profit Margin | -1,939.45% |
EBITDA Margin | -932.66% |
EBIT Margin | -1,548.17% |
FCF Margin | -6,387.55% |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Earnings Yield | -5.36% |
FCF Yield | -17.66% |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Buyback Yield | -1,653.35% |
Shareholder Yield | -1,653.35% |
Analyst Forecast
The average price target for Humacyte is $14.96, which is 217.62% higher than the current price. The consensus rating is "Buy".
Price Target | $14.96 |
Price Target Difference | 217.62% |
Analyst Consensus | Buy |
Analyst Count | 12 |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |